Contribute Try STAT+ Today

In a scathing report, a pair of non-governmental organizations accused the European pharmaceutical industry of “failing to meaningfully invest” resources in the Innovative Medicines Initiative — a widely touted public-private partnership — in areas where research is badly needed.

Instead, the industry steered so-called in-kind contributions — such as personnel and facilities — to projects that were more commercially profitable, rather than those focused on long-term preparedness for epidemics, neglected tropical diseases, and HIV/AIDS, among other issues. And the NGOs also argued that the IMI was “late” in addressing the spread of the Ebola virus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.